Related Experiment Videos
Insights
Antibiotic monitoring ensures safe and effective antimicrobial therapy in neonates by individualizing treatment. This approach accounts for infants
Area of Science:
- Neonatal pharmacokinetics
- Antimicrobial stewardship
- Clinical pharmacology
Background:
- Neonatal pharmacokinetics are highly variable during early development.
- Standard treatment guidelines may not be optimal for individual infants.
- Individualized antimicrobial therapy is crucial for neonates.
Purpose of the Study:
- To highlight the importance of antibiotic monitoring in neonatal antimicrobial therapy.
- To emphasize the need for individualized dosing based on patient-specific pharmacokinetics.
- To discuss methods and indications for monitoring antibiotic levels in newborns.
Main Methods:
- Utilizing Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) data.
- Employing various laboratory assay methods (e.g., HPLC, immunoassays) for serum concentration determination.
- Assessing peak and trough serum concentrations and bactericidal titers.
Main Results:
- Antibiotic monitoring allows for safe and effective antimicrobial therapy in neonates.
- Therapeutic drug monitoring ensures serum concentrations exceed MIC/MBC by 1-5 times.
- Adjustments based on assay results optimize treatment efficacy and safety.
Conclusions:
- Individualized antibiotic therapy, guided by monitoring, is essential for neonates.
- Specific drugs (e.g., aminoglycosides, chloramphenicol) and clinical situations necessitate monitoring.
- Monitoring ensures therapeutic efficacy and minimizes toxicity in neonatal infections.
Abstract:
With antibiotic monitoring, antimicrobial therapy of the neonate can be safe and effective. During this period of transition, the pharmacokinetics of the infant is constantly in a state of flux. Treatment guidelines based on average pharmacokinetics do not always correspond to the values obtained from an individual infant. Individualization of therapy is the goal of monitoring antibiotic therapy in the newborn infant. The MIC and MBC data obtained from susceptibility testing are used to select the most appropriate antibiotic(s). The expected serum antimicrobial concentration should exceed the MIC and MBC by one to five times. Microbiologic, radioenzymatic, radioimmunoassay, high performance liquid chromatography, and other assay methods are currently available in the clinical laboratory. Adjustments of antimicrobial therapy are based on the information provided from assays of peak and trough serum concentration. Bactericidal titers indirectly provide similar information and are adequate for assessing therapy. Indications for monitoring antibiotic therapy in the newborn are dependent on the drug and clinical situation. Aminoglycoside and chloramphenicol, both of which have narrow ranges of serum concentration between efficacy and toxicity, require monitoring. Infants with serious or unusual infections benefit from assays of antibiotics. Other indications for monitoring antimicrobial concentrations are changes in methods of administration, multiple drug therapy, errors in medication, and any situation in which the information can be used to insure efficacy and safety.